Cointime

BioNTech

company

About

BioNTech is a biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.

Highlights

Stock Symbol
nasdaq:BNTX
Total Funding Amount
$1.29B €505M
Funding Rounds
10
Investors
16
Investments
4
Lead Investments
2

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$149.99M
Industries
Biopharma,Biotechnology,Pharmaceutical
Founded date
Jan 1, 2008
Number Of Employee
1001 - 5000
Operating Status
Active
Stock Symbol
nasdaq:BNTX
Legal Name
BioNTech AG

BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
10
$1.29B €505M
BioNTech has raised a total of $1.29B €505M in funding over 2 rounds. Their latest funding was raised on Apr 14, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 14, 2022 Post-IPO Equity $149.99M — — — Detail
Sep 15, 2020 Grant €375M 1 German Federal Ministry of Education and Research (BMBF) — Detail
Jun 29, 2020 Post-IPO Equity $250M 1 Temasek Holdings — Detail
Jun 11, 2020 Post-IPO Debt $100M 1 — — Detail
Dec 17, 2019 Post-IPO Debt €50M 1 European Investment Bank — Detail
Show More

Investments

Number of Investments
Number of Lead Investments
4
2
BioNTech has made 4 investments. Their most recent investment was on Dec 7, 2022, when Greenforce raised €13M.
Date Company Name
Round Money Raised Industry Lead Investor
Dec 7, 2022 Greenforce
Series Unknown €13M Food and Beverage —
Nov 30, 2022 Ryvu
Post-IPO Equity €20M Biotechnology Yes
Feb 2, 2022 MediGene
Post-IPO Equity €26M Biotechnology Yes
Jan 25, 2022 InstaDeep
Series B $100M Artificial Intelligence —

Investors

Number of Lead Investors
Number of Investors
7
16
BioNTech is funded by 16 investors. German Federal Ministry of Education and Research (BMBF) and Temasek Holdings are the most recent investors.
Investor Name Lead Investor Funding Round
German Federal Ministry of Education and Research (BMBF) Yes Grant
Temasek Holdings Yes Post-IPO Equity
Bill & Melinda Gates Foundation Yes Series Unknown
Fidelity Management and Research Company Yes Series B
Sanofi Yes Corporate Round
European Investment Bank — Post-IPO Debt
Athena Capital (South Africa) — Series B
BVCF — Series B
Invus — Series B
Jebsen Capital — Series B
Show More

Employee Profiles

Number of Employee Profiles
9
BioNTech has 9 current employee profiles, including Executive Christoph Huber
Christoph Huber
Executive
Christoph Huber
Board member
Ugur Sahin
Executive
Jesse Dong
Executive
Michael Boehler
Executive
Show More

Exits

BioNTech has had 3 exits. BioNTech most notable exits include InstaDeep ,   Ryvu

Date Company Name Exit Type Industry
Jan 10, 2023 InstaDeep M&A Artificial Intelligence Detail
Jan 4, 2013 Ryvu IPO Biotechnology Detail
Jun 30, 2000 MediGene IPO Biotechnology Detail

Acquisition

BioNTech has acquired 3 organizations. Their most recent acquisition was Neon Therapeutics on Jan 16, 2020. They acquired Neon Therapeutics for $67M.

Date Company Name
Industry Acquisition Type Price
Jan 16, 2020 Neon Therapeutics
Bioinformatics acquisition $ 67M Detail
Jul 19, 2021 Kite - TCR therapy
Pharmaceutical acquisition — Detail
Nov 9, 2021 PhagoMed
Biopharma acquisition — Detail
Cointime
İçerikler
Şirket.